ES2244361T1 - Uso del acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular asociada a la edad. - Google Patents
Uso del acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular asociada a la edad.Info
- Publication number
- ES2244361T1 ES2244361T1 ES03742226T ES03742226T ES2244361T1 ES 2244361 T1 ES2244361 T1 ES 2244361T1 ES 03742226 T ES03742226 T ES 03742226T ES 03742226 T ES03742226 T ES 03742226T ES 2244361 T1 ES2244361 T1 ES 2244361T1
- Authority
- ES
- Spain
- Prior art keywords
- anecortave acetate
- age
- macular degeneration
- patients
- protection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 title claims abstract 5
- 229960001232 anecortave Drugs 0.000 title claims abstract 5
- 208000002780 macular degeneration Diseases 0.000 title claims abstract 3
- 230000001154 acute effect Effects 0.000 title 1
- 230000000007 visual effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract 4
- 230000002265 prevention Effects 0.000 claims abstract 3
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000004304 visual acuity Effects 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40122002P | 2002-08-05 | 2002-08-05 | |
| US401220P | 2002-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2244361T1 true ES2244361T1 (es) | 2005-12-16 |
Family
ID=31495940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03742226T Pending ES2244361T1 (es) | 2002-08-05 | 2003-06-26 | Uso del acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular asociada a la edad. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040127472A1 (https=) |
| EP (1) | EP1539182A4 (https=) |
| JP (1) | JP2005535691A (https=) |
| KR (1) | KR20050026510A (https=) |
| CN (1) | CN1674913A (https=) |
| AR (1) | AR040599A1 (https=) |
| AU (1) | AU2003281817A1 (https=) |
| BR (1) | BR0313546A (https=) |
| CA (1) | CA2494211A1 (https=) |
| DE (1) | DE03742226T1 (https=) |
| ES (1) | ES2244361T1 (https=) |
| MX (1) | MXPA05000773A (https=) |
| PL (1) | PL375024A1 (https=) |
| RU (1) | RU2322239C2 (https=) |
| TW (1) | TW200410699A (https=) |
| WO (1) | WO2004012742A1 (https=) |
| ZA (1) | ZA200500731B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127472A1 (en) * | 2002-08-05 | 2004-07-01 | Jerdan Janice A. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| MXPA05008396A (es) * | 2003-02-20 | 2006-03-30 | Alcon Inc | Formulaciones de glucocorticoides para tratar angiogenesis ocular patologica. |
| AU2004249256A1 (en) * | 2003-06-20 | 2004-12-29 | Alcon, Inc. | Treatment of AMD with combination of ingredients |
| CA2539023A1 (en) * | 2003-09-23 | 2005-04-14 | Alcon Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| US7257366B2 (en) * | 2003-11-26 | 2007-08-14 | Osmosis Llc | System and method for teaching a new language |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US7261529B2 (en) * | 2005-09-07 | 2007-08-28 | Southwest Research Institute | Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
| US7758778B2 (en) * | 2005-09-07 | 2010-07-20 | Southwest Research Institute | Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
| US9693967B2 (en) * | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
| US20070134244A1 (en) * | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
| MX2009006146A (es) * | 2006-12-18 | 2009-06-19 | Alcon Res Ltd | Dispositivos y metodos para la administracion de farmacos oftalmicos. |
| CN101759741B (zh) * | 2008-11-06 | 2013-01-09 | 天津金耀集团有限公司 | 一种化合物及其在制备治疗血管新生的药物中的应用 |
| CN101923856B (zh) | 2009-06-12 | 2012-06-06 | 华为技术有限公司 | 语音识别训练处理、控制方法及装置 |
| US20150037422A1 (en) * | 2012-02-22 | 2015-02-05 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| RU2489146C1 (ru) * | 2012-07-11 | 2013-08-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) | Способ лечения "сухой" формы возрастной макулярной дегенерации |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
| RU2051651C1 (ru) * | 1988-07-07 | 1996-01-10 | Институт химии поверхности АН Украины | Основа для глазных капель |
| US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5679666A (en) * | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
| ATE283013T1 (de) * | 1999-10-21 | 2004-12-15 | Alcon Inc | Medikamentenzuführvorrichtung |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| US20040127472A1 (en) * | 2002-08-05 | 2004-07-01 | Jerdan Janice A. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| US20070134244A1 (en) * | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
-
2003
- 2003-06-26 US US10/606,501 patent/US20040127472A1/en not_active Abandoned
- 2003-06-26 PL PL03375024A patent/PL375024A1/xx unknown
- 2003-06-26 JP JP2004526013A patent/JP2005535691A/ja active Pending
- 2003-06-26 MX MXPA05000773A patent/MXPA05000773A/es not_active Application Discontinuation
- 2003-06-26 US US10/521,707 patent/US20060166956A1/en not_active Abandoned
- 2003-06-26 DE DE03742226T patent/DE03742226T1/de active Pending
- 2003-06-26 KR KR1020057001248A patent/KR20050026510A/ko not_active Ceased
- 2003-06-26 ES ES03742226T patent/ES2244361T1/es active Pending
- 2003-06-26 WO PCT/US2003/020154 patent/WO2004012742A1/en not_active Ceased
- 2003-06-26 AU AU2003281817A patent/AU2003281817A1/en not_active Abandoned
- 2003-06-26 BR BR0313546-2A patent/BR0313546A/pt not_active IP Right Cessation
- 2003-06-26 RU RU2005106234/14A patent/RU2322239C2/ru not_active IP Right Cessation
- 2003-06-26 EP EP03742226A patent/EP1539182A4/en not_active Withdrawn
- 2003-06-26 CN CNA038188260A patent/CN1674913A/zh active Pending
- 2003-06-26 CA CA002494211A patent/CA2494211A1/en not_active Abandoned
- 2003-07-07 TW TW092118474A patent/TW200410699A/zh unknown
- 2003-07-17 AR AR20030102575A patent/AR040599A1/es unknown
-
2005
- 2005-01-25 ZA ZA200500731A patent/ZA200500731B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR040599A1 (es) | 2005-04-13 |
| BR0313546A (pt) | 2005-07-12 |
| ZA200500731B (en) | 2006-08-30 |
| RU2005106234A (ru) | 2005-08-10 |
| KR20050026510A (ko) | 2005-03-15 |
| US20060166956A1 (en) | 2006-07-27 |
| AU2003281817A1 (en) | 2004-02-23 |
| MXPA05000773A (es) | 2005-04-19 |
| CN1674913A (zh) | 2005-09-28 |
| TW200410699A (en) | 2004-07-01 |
| WO2004012742A1 (en) | 2004-02-12 |
| US20040127472A1 (en) | 2004-07-01 |
| PL375024A1 (en) | 2005-11-14 |
| DE03742226T1 (de) | 2006-03-09 |
| JP2005535691A (ja) | 2005-11-24 |
| CA2494211A1 (en) | 2004-02-12 |
| EP1539182A1 (en) | 2005-06-15 |
| EP1539182A4 (en) | 2010-01-20 |
| RU2322239C2 (ru) | 2008-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2244361T1 (es) | Uso del acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular asociada a la edad. | |
| DE60022021D1 (de) | Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion | |
| EP2514420A3 (en) | Use of rapamycin for the treatment or prevention of age-related macular degeneration | |
| BR9406893A (pt) | Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids | |
| AR041725A1 (es) | Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica | |
| ECSP055970A (es) | Uso de palonosetron para el tratamiento de nausea y vomito post operatorio | |
| Mohan et al. | Topical silver sulphadiazine--a new drug for ocular keratomycosis. | |
| AR012731A1 (es) | Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible. | |
| IL163091A (en) | Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction | |
| ES2927928T3 (es) | Uso de una composición antimicrobiana | |
| CA2519789A1 (en) | Aplidine for multiple myeloma treatment | |
| Richards et al. | Treatment of trachoma with sulfanilamide | |
| EP4523750A3 (en) | Methods of reducing cerebrovascular events in patients with fabry disease | |
| WO2016063265A2 (pt) | Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| Mellinger | A New Mask That Protects Both Physician and Patient | |
| Smith | Postmenopausal urinary symptoms and hormonal replacement therapy | |
| Wallace | The development of plastic surgery for war | |
| Day | No more cocktails | |
| Herzog | Drug treatment of typhoid fever | |
| Albab et al. | Case report: Intrastromal injection of voriconazole as a therapeutic of fungal hypopyon. | |
| Oguz et al. | THE EFFECTS OF LONG-TERM SILDE-NAFIL TREATMENT ON INTRAOCULAR PRESSURE WHITE-ON-WHITE AND BLUE-ON-YELLOW HUMPHREY PERIMETRY | |
| Loeliger et al. | Anticoagulants in Acute Myocardial Infarction | |
| Clarke | important to give early notice of the following observation. | |
| Di Prima et al. | Clinical and bacteriological evaluation of ofloxacin in 20 cases of skin infection. |